These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17085798)

  • 21. Asthma medication is increasingly prescribed for finnish olympic athletes--for a reason?
    Aavikko A; Helenius I; Alaranta A; Vasankari T; Haahtela T
    J Asthma; 2012 Sep; 49(7):744-9. PubMed ID: 22873287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta2-Agonist Doping Control and Optical Isomer Challenges.
    Jacobson GA; Fawcett JP
    Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terbutaline: level the playing field for inhaled β
    Jacobson GA; Hostrup M
    Br J Sports Med; 2017 Sep; 51(18):1323-1324. PubMed ID: 27461883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why must olympic athletes prove that they have asthma to be permitted to take inhaled beta2-agonists?
    Weiler JM
    J Allergy Clin Immunol; 2003 Jan; 111(1):36-7. PubMed ID: 12532093
    [No Abstract]   [Full Text] [Related]  

  • 25. The enigma of inhaled salbutamol and sport: unresolved after 45 years.
    Fitch KD
    Drug Test Anal; 2017 Jul; 9(7):977-982. PubMed ID: 28294577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines.
    Prenner BM
    Curr Opin Pulm Med; 2008 Jan; 14(1):57-63. PubMed ID: 18043276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of therapeutic use exemptions at the Olympic Games and association with medals: an analysis of data from 2010 to 2018.
    Vernec A; Healy D
    Br J Sports Med; 2020 Aug; 54(15):920-924. PubMed ID: 32376674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bronchial hyperreactivity in athletes].
    Carlsen KH
    Nord Med; 1994; 109(1):16-8. PubMed ID: 8028991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta2-agonists and exercise-induced asthma.
    Anderson SD; Caillaud C; Brannan JD
    Clin Rev Allergy Immunol; 2006; 31(2-3):163-80. PubMed ID: 17085791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It.
    Vertadier N; Trzepizur W; Faure S
    Sports (Basel); 2022 Mar; 10(3):. PubMed ID: 35324645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asthma, airway inflammation and treatment in elite athletes.
    Helenius I; Lumme A; Haahtela T
    Sports Med; 2005; 35(7):565-74. PubMed ID: 16026170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sports in extreme conditions: the impact of exercise in cold temperatures on asthma and bronchial hyper-responsiveness in athletes.
    Carlsen KH
    Br J Sports Med; 2012 Sep; 46(11):796-9. PubMed ID: 22906782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical concerns with inhaled beta2-agonists: adult asthma.
    Cockcroft DW
    Clin Rev Allergy Immunol; 2006; 31(2-3):197-208. PubMed ID: 17085793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of changes in anti-doping regulations (WADA Guidelines) on asthma care in athletes.
    Couto M; Horta L; Delgado L; Capão-Filipe M; Moreira A
    Clin J Sport Med; 2013 Jan; 23(1):74-6. PubMed ID: 22948449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asthma in United States olympic athletes who participated in the 1998 olympic winter games.
    Weiler JM; Ryan EJ
    J Allergy Clin Immunol; 2000 Aug; 106(2):267-71. PubMed ID: 10932069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-doping policy development process in the sports world (1968~1999): focusing on IOC activities and passive response from Korea].
    Hwang ER; Kim TY
    Uisahak; 2014 Aug; 23(2):269-318. PubMed ID: 25223222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes.
    Bonini S; Brusasco V; Carlsen KH; Delgado L; Del Giacco SR; Haahtela T; Rasi G; van Cauwenberge PB
    Allergy; 2004 Jan; 59(1):33-6. PubMed ID: 14674930
    [No Abstract]   [Full Text] [Related]  

  • 38. Medication use in athletes selected for doping control at the Sydney Olympics (2000).
    Corrigan B; Kazlauskas R
    Clin J Sport Med; 2003 Jan; 13(1):33-40. PubMed ID: 12544162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are the prevalence and treatment of asthma similar in elite athletes and the aged-matched non-athlete population?
    Locke S; Marks G
    Scand J Med Sci Sports; 2007 Dec; 17(6):623-7. PubMed ID: 17316378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.